ERYTECH to Host Fourth Quarter and Full Year 2020 Conference Call and Business Update

Rhea-AI Summary

ERYTECH Pharma will host a conference call on March 9, 2021, at 2:30 PM CET to discuss operational highlights for the fourth quarter and full year 2020. The call will be accessible via various teleconferencing numbers, with a Conference ID of 8861234#. Additionally, the event will be available as a webcast and can be followed live online. ERYTECH is focused on innovative therapies for severe cancers, notably through its lead candidate, eryaspase, currently in clinical trials for pancreatic cancer and triple-negative breast cancer.

ERYTECH to Host Fourth Quarter and Full Year 2020
Conference Call and Business Update

Lyon (France) and Cambridge, MA (U.S.), March 4, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its fourth quarter and full year 2020 conference call and webcast on Tuesday, March 9, 2021, at 2:30 PM CET/8:30 AM ET to discuss operational highlights.

The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 8861234#

USA/Canada: +1 (833) 818-6807                                                              France: +33 1 70 80 71 53            
International Dial-In Number: +1 (409) 350-3501                            United-Kingdom: +44 2031070289         

The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/tic4qkwg

An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 8861234#.

An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at investors.erytech.com

About ERYTECH and eryaspase

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial in acute lymphoblastic leukemia recently reported positive results.

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL. Eryaspase received Fast Track designation from the FDA for the treatment of second-line pancreatic cancer.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.            

For more information, please visit www.erytech.com      
               

CONTACTS

ERYTECH                             Eric Soyer CFO & COO	LifeSci Advisors, LLC Investor Relations Corey Davis, Ph.D.	NewCap Mathilde Bohin / Louis-Victor Delouvrier Investor relations Nicolas Merigeau Media relations
+33 4 78 74 44 38 investors@ERYTECH.com	+1 (212) 915 - 2577 cdavis@lifesciadvisors.com	+33 1 44 71 94 94 ERYTECH@newcap.eu

Attachment

• ERYTECH_PR_2020_Q4_Ccall-announcement_EN_vf

FAQ

What is the date and time for ERYTECH's Q4 2020 conference call?

ERYTECH will host its Q4 2020 conference call on March 9, 2021, at 2:30 PM CET.

How can I access the ERYTECH Q4 2020 conference call?

The conference call can be accessed via teleconferencing numbers provided in the announcement, with the Conference ID 8861234#.

Where can I watch the ERYTECH Q4 2020 conference call webcast?

The conference call will be available as a live webcast on ERYTECH's website.

What is the focus of ERYTECH's drug candidate, eryaspase?

Eryaspase targets cancer cell metabolism by depriving them of necessary amino acids, currently in trials for pancreatic and triple-negative breast cancer.

What significance does the FDA grant to ERYTECH's eryaspase?

Eryaspase received orphan drug status from the FDA for pancreatic cancer treatment and Fast Track designation for second-line pancreatic cancer.